Bullish
PureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC)
PureTech Health announced significant progress from its Founded Entity, Seaport Therapeutics, whose oral drug GlyphAgo, designed to treat generalized ...